Lazertinib
Aliases
JNJ-73841937, LECLAZA, YH25448
17 clinical trials
2 abstracts
13 indications
Indication
Lung CancerIndication
Metastatic Non Small Cell Lung CancerIndication
Recurrent Non-Small Cell Lung CancerIndication
LazertinibIndication
Non-Small Cell Lung Cancer MetastaticIndication
Non-small Cell Lung Cancer Stage IIIIndication
Non-squamous non-small cell lung cancerIndication
cancerIndication
Non-Small Cell LungIndication
advanced solid malignanciesIndication
Non-small Cell LungIndication
NSCLCClinical trial
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer (NeoLazer): a Phase II, Randomized, Multi-center StudyStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous TreatmentStatus: Active (not recruiting), Estimated PCD: 2025-07-01
Abstract
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.Org: Princess Margaret Cancer Centre, Wakayama Medical University, Wakayama, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Jilin Cancer Hospital, Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research,
Clinical trial
A Randomized Phase II Study of LAZE Rti N ib Alone Versus Lazertinib Plus Beva C Izumab for A Dvanced Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations and Smoking HistoryStatus: Recruiting, Estimated PCD: 2026-09-05
Clinical trial
A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKIStatus: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Lazertinib and Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment: A Phase II Multi-center TrialStatus: Not yet recruiting, Estimated PCD: 2029-09-30
Clinical trial
A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR MutationsStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Randomized, Phase 2 Trial of Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy (CHAMELEON)Status: Not yet recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase II, Multicenter Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR Mutation Positive Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Chemoradiation Therapy (PLATINUM Trial)Status: Recruiting, Estimated PCD: 2026-03-02
Clinical trial
A Phase 2, Open-Label, Randomized Trial Evaluating the Impact of Enhanced Versus Standard Dermatologic Management on Selected Dermatologic Adverse Events Among Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab + LazertinibStatus: Recruiting, Estimated PCD: 2025-07-03
Clinical trial
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Status: Active (not recruiting), Estimated PCD: 2024-04-30
Clinical trial
Impact of Lazertinib Dose Modification on Effectiveness and Safety in EGFR T790M-Positive Advanced Lung CancerStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-07-11
Clinical trial
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib FailureStatus: Active (not recruiting), Estimated PCD: 2023-07-10
Clinical trial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 StudyStatus: Active (not recruiting), Estimated PCD: 2024-12-15
Clinical trial
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-02-03
Clinical trial
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung CancerStatus: Recruiting, Estimated PCD: 2025-10-31
Abstract
Predictive biomarkers for treatment with amivantamab plus lazertinib among EGFR-mutated NSCLC in the post-osimertinib setting: Analysis of tissue IHC and ctDNA NGS.Org: Gustave Roussy Cancer Center, University of Pennsylvania, National Cancer Center Hospital East, Kashiwa, Japan, Seoul National University Bundang Hospital, Yonsei University College of Medicine,